| 1 |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
|
| 2 |
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study [J]. Lancet, 2020, 395(10219): 200-211.
|
| 3 |
Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research [J]. Lancet Infect Dis, 2015, 15(5): 581-614.
|
| 4 |
Rudd KE, Delaney A, Finfer S. Counting Sepsis, an imprecise but improving science [J]. JAMA, 2017, 318(13): 1228-1229.
|
| 5 |
Klein Klouwenberg PM, Cremer OL, van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study [J]. Crit Care, 2015, 19(1): 319.
|
| 6 |
Kaysen GA, Ye X, Raimann JG, et al. Lipid levels are inversely associated with infectious and all-cause mortality: international MONDO study results [J]. J Lipid Res, 2018, 59(8): 1519-1528.
|
| 7 |
Catapano AL, Pirillo A, Bonacina F, et al. HDL in innate and adaptive immunity [J]. Cardiovasc Res, 2014, 103(3): 372-383.
|
| 8 |
Cheng N, Liang Y, Du X, et al. Serum amyloid A promotes LPS clearance and suppresses LPS-induced inflammation and tissue injury [J]. EMBO Rep, 2018, 19(10).
|
| 9 |
Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease [J]. Eur Heart J, 2015, 36(9): 539-350.
|
| 10 |
Meilhac O, Tanaka S, Couret D. High-density lipoproteins are bug scavengers [J]. Biomolecules, 2020, 10(4).
|
| 11 |
Tanaka S, Labreuche J, Drumez E, et al. Low HDL levels in sepsis versus trauma patients in intensive care unit [J]. Ann Intensive Care, 2017, 7(1): 60.
|
| 12 |
Chien JY, Jerng JS, Yu CJ, et al. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis [J]. Crit Care Med, 2005, 33(8): 1688-1693.
|
| 13 |
Dai L, Datta G, Zhang Z, et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats [J]. J Lipid Res, 2010, 51(9): 2695-2705.
|
| 14 |
De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3 [J]. Nat Immunol, 2014, 15(2): 152-160.
|
| 15 |
Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation [J]. J Leukoc Biol, 2015, 98(6): 923-929.
|
| 16 |
Chenaud C, Merlani PG, Roux-Lombard P, et al. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation [J]. Crit Care Med, 2004, 32(3): 632-637.
|
| 17 |
Guirgis FW, Black LP, Henson M, et al. A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes [J]. Crit Care, 2021, 25(1): 341.
|
| 18 |
Morin EE, Guo L, Schwendeman A, et al. HDL in sepsis - risk factor and therapeutic approach [J]. Front Pharmacol, 2015, 6: 244.
|
| 19 |
Curcic S, Holzer M, Frei R, et al. Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL [J]. Biochim Biophys Acta, 2015, 1851(2): 184-193.
|
| 20 |
Duchateau PN, Pullinger CR, Orellana RE, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L [J]. J Biol Chem, 1997, 272(41): 25576-25582.
|
| 21 |
Henning MF, Herlax V, Bakás L. Contribution of the C-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect [J]. Innate Immun, 2011, 17(3): 327-337.
|
| 22 |
Flegel WA, Baumstark MW, Weinstock C, et al. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I [J]. Infect Immun, 1993, 61 (12):5140-5146.
|
| 23 |
Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk [J]. J Med Genet, 2006, 43(12): 943-949.
|
| 24 |
Li Y, Dong JB, Wu MP. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice [J]. Eur J Pharmacol, 2008, 590(1-3): 417-422.
|
| 25 |
Imai T, Fujita T, Yamazaki Y. Beneficial effects of apolipoprotein A-I on endotoxemia [J]. Surg Today, 2003, 33(9): 684-687.
|
| 26 |
Yan YJ, Li Y, Lou B, et al. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice [J]. Life Sci, 2006,79(2): 210-215.
|
| 27 |
Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein [J]. Atherosclerosis, 1993, 102(2): 131-146.
|
| 28 |
Sack GHJr. Serum amyloid A - a review [J]. Mol Med, 2018, 24(1): 46.
|
| 29 |
Benditt EP, Eriksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein [J]. Proc Natl Acad Sci U S A, 1979, 76(8): 4092-4096.
|
| 30 |
Baltz ML, Rowe IF, Caspi D, et al. Is the serum amyloid A protein in acute phase plasma high density lipoprotein the precursor of AA amyloid fibrils? [J]. Clin Exp Immunol, 1986, 66(3): 701-708.
|
| 31 |
Lee J, Beatty GL. Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer [J]. Cancers (Basel), 2021, 13(13).
|
| 32 |
Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A [J]. Crit Rev Immunol, 2012, 32(4): 335-348.
|
| 33 |
Cetinkaya M, Ozkan H, Köksal N, et al. The efficacy of serial serum amyloid A measurements for diagnosis and follow-up of necrotizing enterocolitis in premature infants [J]. Pediatr Surg Int, 2010, 26(8): 835-841.
|
| 34 |
Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant [J]. Eur J Biochem, 1999, 265(2): 501-523.
|
| 35 |
Shainkin-Kestenbaum R, Winikoff Y, Cristal N. Serum amyloid A concentrations during the course of acute ischaemic heart disease [J]. J Clin Pathol, 1986, 39(6): 635-637.
|
| 36 |
De Buck M, Gouwy M, Wang JM, et al. The cytokine-serum amyloid A-chemokine network [J]. Cytokine Growth Factor Rev, 2016, 30: 55-69.
|
| 37 |
Steel DM, Rogers JT, DeBeer MC, et al. Biosynthesis of human acute-phase serum amyloid A protein (A-SAA) in vitro: the roles of mRNA accumulation, poly (A) tail shortening and translational efficiency [J]. Biochem J, 1993, 291 (Pt 3) (Pt 3): 701-707.
|
| 38 |
Mayer JM, Raraty M, Slavin J, et al. Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis [J]. Br J Surg, 2002, 89(2): 163-171.
|
| 39 |
Rau B, Steinbach G, Baumgart K, et al. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant [J]. Crit Care Med, 2000, 28(3): 736-742.
|
| 40 |
Cetinkaya M, Ozkan H, Köksal N, et al. Comparison of the efficacy of serum amyloid A, C-reactive protein, and procalcitonin in the diagnosis and follow-up of necrotizing enterocolitis in premature infants [J]. J Pediatr Surg, 2011, 46(8): 1482-1489.
|
| 41 |
Liu C, Zhang Y, Shang Y, et al. Clinical values of common biomarkers for efficacy monitoring of antibiotics in early-onset neonatal sepsis [J]. Transl Pediatr, 2020, 9(5): 669-676.
|
| 42 |
Bengnér J, Quttineh M, Gäddlin PO, et al. Serum amyloid A - A prime candidate for identification of neonatal sepsis [J]. Clin Immunol, 2021,229: 108787.
|
| 43 |
Schuchardt M, Prüfer N, Tu Y, et al. Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells [J]. Sci Rep, 2019, 9(1): 3421.
|
| 44 |
Ather JL, Ckless K, Martin R, et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice [J]. J Immunol, 2011, 187(1): 64-73.
|
| 45 |
Migita K, Koga T, Satomura K, et al. Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts [J]. Arthritis Res Ther, 2012, 14(3): R119.
|
| 46 |
Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body [J]. Annu Rev Immunol, 2009, 27: 229-265.
|
| 47 |
Gouwy M, De Buck M, Pörtner N, et al. Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines [J]. Eur J Immunol, 2015, 45(1): 101-112.
|
| 48 |
Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age [J]. Nat Immunol, 2018, 19(2): 108-119.
|
| 49 |
Linke RP, Meinel A, Chalcroft JP, et al. Serum amyloid A (SAA) treatment enhances the recovery of aggravated polymicrobial sepsis in mice, whereas blocking SAA's invariant peptide results in early death [J]. Amyloid, 2017, 24(sup1): 149-150.
|
| 50 |
Gatt ME, Urieli-Shoval S, Preciado-Patt L, et al. Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils [J]. J Lab Clin Med, 1998, 132(5): 414-420.
|
| 51 |
Sun L, Zhou H, Zhu Z, et al. Ex vivo and in vitro effect of serum amyloid a in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils [J]. J Immunol, 2015, 194(10): 4891-4900.
|
| 52 |
Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes [J]. Cell, 2014, 157(5): 1013-1022.
|
| 53 |
Sander LE, Sackett SD, Dierssen U, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function [J]. J Exp Med, 2010, 207(7): 1453-1464.
|
| 54 |
Newton K, Dixit VM. Signaling in innate immunity and inflammation [J]. Cold Spring Harb Perspect Biol, 2012, 4(3): a006049.
|
| 55 |
Annema W, Nijstad N, Tölle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2) [J]. J Lipid Res, 2010, 51(4): 743-754.
|
| 56 |
McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo [J]. Circulation, 2009, 119(8): 1135-1145.
|
| 57 |
Hu W, Abe-Dohmae S, Tsujita M, et al. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo [J]. J Lipid Res, 2008, 49(2): 386-393.
|
| 58 |
Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles [J]. Amyloid, 2012, 19(1): 5-14.
|
| 59 |
Karlsson H, Kontush A, James RW. Functionality of HDL: antioxidation and detoxifying effects [J]. Handb Exp Pharmacol, 2015, 224: 207-228.
|
| 60 |
Tölle M, Huang T, Schuchardt M, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A [J]. Cardiovasc Res, 2012, 94(1): 154-162.
|
| 61 |
Jayaraman S, Haupt C, Gursky O. Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA [J]. J Lipid Res, 2016, 57(12): 2138-2149.
|
| 62 |
Sato M, Ohkawa R, Yoshimoto A, et al. Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoprotein [J]. Biosci Rep, 2016, 36(4): e00369.
|
| 63 |
Tsunoda F, Lamon-Fava S, Horvath KV, et al. Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins [J]. Lipids Health Dis, 2016, 15(1): 163.
|
| 64 |
Zheng A, Widmann C. The interplay between serum amyloid A and HDLs [J]. Curr Opin Lipidol, 2020, 31(5): 300-301.
|